An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biocept to Present at Four Virtual Investor Conferences in September
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
SAN DIEGO--(BUSINESS WIRE)--
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:
H.C. Wainwright 23rd Annual Global Investment Conferencebeing held September 13-15, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m. Pacific time).
Oppenheimer Fall Healthcare Life Sciences & MedTech Conference on Wednesday, September 22, 2021 at 3:45 p.m. Eastern time (12:45 p.m. Pacific time).
Cantor Virtual Healthcare Conference on Wednesday, September 29, 2021 at 4:40 p.m. Eastern time (1:40 p.m. Pacific time).
Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021 at 2:20 p.m. Eastern time (11:20 a.m. Pacific time). The presentation will be available on the Benzinga website here.
Webcasts of the presentations at the Oppenheimer and Cantor conferences will be available on the Events and Presentations page of the Biocept website and will be archived for 90 days.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
